Trials / Terminated
TerminatedNCT03943147
An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of BMS-986165 compared with placebo with regard to measures of kidney function in participants with lupus nephritis (LN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986165 | Specified dose on specified days |
| DRUG | Placebo | Specified dose on specified days |
| DRUG | Mycophenolate Mofetil | Specified dose on specified days |
Timeline
- Start date
- 2019-07-15
- Primary completion
- 2020-10-29
- Completion
- 2021-09-17
- First posted
- 2019-05-09
- Last updated
- 2022-10-17
- Results posted
- 2022-10-17
Locations
100 sites across 16 countries: United States, Australia, Belgium, Canada, China, Czechia, Germany, Israel, Italy, Mexico, Netherlands, Russia, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03943147. Inclusion in this directory is not an endorsement.